



#6/KT  
3/4  
026.00231/A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: O'Brien et al. )  
Serial No.: 09/846,506 ) Examiner: J. Schultz  
Filed: May 1, 2001 ) Art Unit: 1635  
For: USE OF CD63 INHIBITORS )

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the August 13, 2002 office action,  
please amend the above-identified patent application as  
follows:

In the claims:

Please amend claim 5 as follows:

A'  
5. (Amended) A method of treating human immunodeficiency  
virus infection in a subject, the method comprising  
administering to the subject an amount of a compound effective  
to decrease levels of functional CD63 in cells of the subject.

REMARKS

In view of the above amendments and the following  
remarks, reconsideration of the outstanding office action is  
respectfully requested.

The rejection of claims 1-10 under 35 U.S.C. § 112  
(first paragraph) for lack of written description is  
respectfully traversed.

The basis for the U.S. Patent and Trademark Office's  
("PTO") rejection of the claims is that the present